Ashwin Balagopal, MD

• Chair, ACTG 5335s
• Investigator ACTG 5329 and ACTG 5334s
• Investigator, Hepatitis Transformative Science Group (Feb 2016)

The purpose of this study is to develop and assess the efficacy of an integrated strategy that includes feasible and scalable...

The purpose of this study is to obtain informed consent to use stored human biological materials (HBM) (e.g., blood and other...

A5314 is a phase II randomized, double-blind, placebo-controlled 36-week trial that will examine the safety and efficacy of...

Rationale: There is an urgent need for a platform to rapidly evaluate therapies in the outpatient setting, to prevent disease...

ACTG A5324 is a phase IV randomized, double-blinded, placebo-controlled study to assess the efficacy of adding Maraviroc (MVC)...

Johns Hopkins University Baltimore-India Clinical Trials Unit